ArticlePloS one2017

Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: A retrospective cohort study.

Shelagh M Szabo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.